Evidence map›Paper›PMID 42826091›Full record

ReviewHuman vaccines & immunotherapeutics2026

Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease.

Muhammad Inam, Muhammad Jamshed, Abuzar Osman

Abstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Muhammad InamSchool of Medicine, Qilu Institute of Technology, Jinan, P.R. China.
Muhammad JamshedNorthwest School of Medicine, Peshawar, Pakistan.
Abuzar OsmanDepartment of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, Saudia Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology has transformed vaccine development by engineering nanovaccines that offer precise control over antigen performance, immune modulation and targeted delivery. These platforms influence physicochemical properties size, charge, and ligand expression to direct antigen trafficking, co-deliver adjuvants and antigen-presenting cells, stimulating potent and robust adaptive immune responses. This review discusses the development of nanovaccines for prophylactic vaccines which induce antibody and memory B-cell responses and therapeutic cancer vaccines, which overcome tolerance and immunosuppression to activate CD8

Indexed as

Cancer VaccinesCommunicable DiseasesImmunotherapyNanovaccinesNeoplasmsAdjuvants, ImmunologicAnimalsHumansNanoparticlesVaccine DevelopmentAdjuvants, ImmunologicCancer VaccinesNanovaccinesantigencancerimmunotherapyinfectionNanovaccines

Identifiers

PMID42826091
PMCPMC13644636

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.